These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24602916)

  • 1. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
    Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
    Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
    Lawrence J; Saba C; Gogal R; Lamberth O; Vandenplas ML; Hurley DJ; Dubreuil P; Hermine O; Dobbin K; Turek M
    Vet Comp Oncol; 2012 Jun; 10(2):143-54. PubMed ID: 22236016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of different cell storage/culture conditions on spontaneous proliferation and level of tyrosine kinase receptor inhibition in two feline injection-site sarcoma cell lines.
    Feldhaeusser BR; Turek M; Lawrence J; Cornell K; Gogal RM
    J Immunoassay Immunochem; 2013; 34(3):266-82. PubMed ID: 23656247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
    Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
    Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gold nanoparticles enhance radiation sensitization and suppress colony formation in a feline injection site sarcoma cell line, in vitro.
    Benton JZ; Williams RJ; Patel A; Meichner K; Tarigo J; Nagata K; Pethel TD; Gogal RM
    Res Vet Sci; 2018 Apr; 117():104-110. PubMed ID: 29220723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
    Lyles SE; Milner RJ; Kow K; Salute ME
    Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of masitinib mesylate in healthy cats.
    Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
    J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
    Thamm DH; Rose B; Kow K; Humbert M; Mansfield CD; Moussy A; Hermine O; Dubreuil P
    Vet J; 2012 Jan; 191(1):131-4. PubMed ID: 21333567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in γ-H2AX expression in irradiated feline sarcoma cells: an indicator of double strand DNA breaks.
    Lawrence J; Karpuzoglu E; Vance A; Vandenplas M; Saba C; Turek M; Gogal RM
    Res Vet Sci; 2013 Jun; 94(3):545-8. PubMed ID: 23375429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
    Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
    Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
    Rathore K; Alexander M; Cekanova M
    Transl Res; 2014 Aug; 164(2):158-68. PubMed ID: 24631063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
    Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
    Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
    J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative effect of metformin on a feline injection site sarcoma cell line independent of Mtor inhibition.
    Pierro J; Saba C; McLean K; Williams R; Karpuzoglu E; Prater R; Hoover K; Gogal R
    Res Vet Sci; 2017 Oct; 114():74-79. PubMed ID: 28319830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiation therapy for treatment of injection-site sarcomas in cats: 11 cases (2008-2012).
    Nolan MW; Griffin LR; Custis JT; LaRue SM
    J Am Vet Med Assoc; 2013 Aug; 243(4):526-31. PubMed ID: 23902446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro efficacy of doxorubicin and etoposide against a feline injection site sarcoma cell line.
    Hill J; Lawrence J; Saba C; Turek M; Feldhaeusser B; Coutermarsh-Ott S; Barber J; Smith J; Gogal R
    Res Vet Sci; 2014 Oct; 97(2):348-56. PubMed ID: 25085537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
    Zhang AL; Russell PJ; Knittel T; Milross C
    Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.